Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
NVO heads into Q2 earnings under pressure as slowing injectable GLP-1 momentum, pricing headwinds and fierce competition cloud the near-term outlook.
Market narrative
Move between stock news, official company releases, crypto, and FX without losing the path back to ticker research.
NVO heads into Q2 earnings under pressure as slowing injectable GLP-1 momentum, pricing headwinds and fierce competition cloud the near-term outlook.
Stocks
KHC expects to post weaker Q2 sales and earnings as inflation, softer food demand and Easter timing are likely to have pressured its performance despite continued growth investments.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Pitney Bowes (PBI) have what it takes?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Atmos (ATO) have what it takes?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does BlackRock (BLK) have what it takes?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Colony Bankcorp (CBAN) have what it takes?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Exelon (EXC) have what it takes?
I reiterate a buy on Procter & Gamble for its fortress dividend and defensive income profile, not near-term growth. PG's FY2026 delivered resilient cash flow and a 100% free cash flow conversion, even as organic sales growth stalled to 0% in Q4. At 21x forward earnings and a 2.97% yield, PG trades below its five-year average multiple, offering a compelling income opportunity.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Tenaris (TS) have what it takes?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Cincinnati Financial (CINF) have what it takes?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does California Water Service Group (CWT) have what it takes?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Morgan Stanley (MS) have what it takes?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bank of Montreal (BMO) have what it takes?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Kimco Realty (KIM) have what it takes?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does East West Bancorp (EWBC) have what it takes?
Cash flow versus burn is something Bill Drolet will be closely watching in regards to SpaceX (SPCX) as the company reports its first earnings as a public company. He thinks investors might have been giving the company a bit of an "Elon Musk halo" as SpaceX finds its footing amongst traders.
New York, New York--(Newsfile Corp. - August 3, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Microvast Holdings, Inc. ("Microvast" or the "Company") (NASDAQ: MVST) on behalf of investors that purchased or otherwise acquired Microvast securities between April 1, 2025 and March 16, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Microvast and have suffered losses, you may CLICK HERE to contact us.
It's time to double down on the stock.
Micron Technology, Inc. has surged ~80% since my initial strong Buy rating, vastly outperforming the broader market. MU's rally was initially suppressed by macro headwinds, with a significant rerating occurring after Q2 earnings as market risks abated. Following Q3 earnings, MU's price action suggests a rerating has not materialized.
NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the “Class Period”), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.